Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Byooviz
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Fylnetra
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Releuko
    • Renflexis
    • Retacrit
    • Rezvoglar
    • Riabni
    • Ruxience
    • Semglee
    • Trazimera
    • Truxima
    • Udenyca
    • Yusimry
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2023 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

SM Health Comm

Recent Posts

  • Sandoz to Market Samsung Bioepis’ Ustekinumab Biosimilar September 14, 2023
  • Outlook Therapeutics Gets FDA Rejection on Its Ophthalmologic Bevacizumab Formulation August 31, 2023
  • Two More Patent Settlements and Launch Dates for Ustekinumab Biosimilars August 30, 2023
  • Three Biosimilar Targets in CMS’s Sights August 29, 2023
  • What is Cordavis and Why Will It Be Important to CVS Health and Biosimilars? August 28, 2023
  • Sandoz Notches Approval of Tyruko, First Biosimilar to Treat Multiple Sclerosis August 25, 2023
  • Simplifying Biosimilar Development to Ensure Long-Term Competition August 23, 2023
  • Where’s Pfizer’s Adalimumab Biosimilar? August 14, 2023
  • Ranibizumab Biosimilar Updates: A Nascent Market but Limited Competition August 3, 2023
  • Projecting at Least 40% Lower 2023 Humira® Net Costs in US July 28, 2023

Recent Comments

Drug Manufacturers’… on The Inflation Reduction Act: R…
Drug Manufacturers’… on Thirty Years of Exclusivity fo…
Manjiri Kulkarni on What is Cordavis and Why Will…
MK on Where’s Pfizer’s Adalimumab Bi…
Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • The Evolution of the Biosimilars Market
  • The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
  • What Will Cost Savings on 2023 Adalimumab Biosimilars Really Be Worth?
  • Ziextenzo
  • Ustekinumab Biosimilars Update
  • Tocilizumab Biosimilars Approaching: Developments on Three Fronts
  • Biosimilar Approval Status
  • Sandoz to Market Samsung Bioepis' Ustekinumab Biosimilar
  • Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
  • Biosimilar Clinical Trial Costs in Terms of Expense and Time
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.